Top

Published in:

01-09-2013 | PHARMACO-EPIDEMIOLOGY

Triptan safety during pregnancy: a Norwegian population registry study

Authors: Kateřina Nezvalová-Henriksen, Olav Spigset, Hedvig Nordeng

Published in: European Journal of Epidemiology | Issue 9/2013

Abstract

Knowledge on triptan safety during pregnancy remains limited to their class effect or studies on sumatriptan. Our aim was to evaluate the individual effect of four most frequently used triptans on several pregnancy outcomes. We used the Norwegian prescription database to access information on triptans redeemed by pregnant women living in Norway between 2004 and 2007. This database was linked to the Medical Birth Registry of Norway covering every institutional delivery in Norway and providing information on pregnancy, delivery, maternal and neonatal health. Estimates of associations with pregnancy outcomes were obtained by Generalised Estimation Equations analysis. Of the 181,125 women in our study, 1,465 (0.8 %) redeemed triptans during pregnancy, and 1,095 (0.6 %) redeemed triptans before pregnancy only (disease comparison group). The population comparison group comprised the remaining 178,565 women. Using this group as reference, we found no associations between triptan redemption during pregnancy and congenital malformations. Second trimester redemption was associated with postpartum haemorrhage (adjusted OR 1.57; 95 % CI 1.19–2.07). The disease comparison group had an increased risk of major congenital malformations (adjusted OR 1.48; 95 % CI 1.11–1.97), low birth weight (adjusted OR 1.39; 95 % CI 1.08–1.81), and preterm birth (adjusted OR 1.30; 95 % CI 1.06–1.60). The association of triptans with postpartum hemorrhage could be attributable to decreased platelet agreeability occurring in severe migraine. Likewise, the increased risk of major congenital malformations and other adverse pregnancy outcomes in the disease comparison group might be attributable to migraine severity.

Available only for authorised users

Ertresvåg J, Zwart J-A, Helde G, Johnsen H-J, Bovim G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand. 2005;111:233–7.PubMedCrossRef

Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23(3):197–205.PubMedCrossRef

Melhado E, Maciel JA Jr, Guerreiro CA. Headaches during pregnancy in women with a prior history of menstrual headaches. Arq Neuropsiquiatr. 2005;63(4):934–40. doi:/S0004-282x2005000600006.PubMedCrossRef

Marcus D, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache. 1999;39(9):625–32.PubMedCrossRef

Scharff L, Marcus DA, Turk DC. Headache during pregnancy and in the postpartum: a prospective study. Headache. 1997;37(4):203–10.PubMedCrossRef

Mattsson P, Svardsudd K, Lundberg PO, Westerberg CE. The prevalence of migraine in women aged 40–74 years: a population-based study. Cephalalgia. 2000;20(10):893–9.PubMedCrossRef

Granella F, Sances G, Pucci E, Nappi R, Chiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20(8):701–7.PubMed

Maggioni F, Alessi C, Maggino T, Zanchin G. Headache during pregnancy. Cephalalgia. 1997;17(7):765–9.PubMedCrossRef

Facchinetti F, Allais G, Nappi RE, D’Amico R, Marozio L, Bertozzi L, et al. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009;29(3):286–92. doi:10.1111/j.1468-2982.2008.01704.x.PubMedCrossRef

10.

Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol. 2011;25(2):116–23. doi:10.1111/j.1365-3016.2010.01182.x.PubMedCrossRef

11.

Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009;338:1–8. doi:10.1136/bmj.b664.CrossRef

12.

Chen HM, Chen SF, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia. 2010;30(4):433–8. doi:10.1111/j.1468-2982.2009.01935.x.PubMed

13.

Facchinetti F, Allais G, D’Amico R, Benedetto C, Volpe A. The relationship between headache and preeclampsia: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):143–8. doi:10.1016/j.ejogrb.2004.12.020.PubMedCrossRef

14.

Adeney KL, Williams MA, Miller RS, Frederick IO, Sorensen TK, Luthy DA. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med. 2005;18(3):167–72. doi:10.1080/14767050500260566.PubMedCrossRef

15.

Leveno KJ, Cunningham FG, Alexander JM, Bloom SL, Casey BM, Dashe JS, et al. Williams manual of obstetrics pregnancy complications. 22nd ed. New York: McGraw-Hill; 2007.

16.

Nezvalová-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross sectional analysis of data from a large cohort study. Cephalalgia. 2009;29:1267–76.PubMedCrossRef

17.

Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian mother and child cohort study. Headache. 2010;50:563–75.PubMedCrossRef

18.

Nezvalova-Henriksen K, Spigset O, Nordeng HM. Errata in “Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian mother and child cohort study”. Headache. 2012;52(8):1319–20. doi:10.1111/j.1526-4610.2012.02207.x.PubMedCrossRef

19.

Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB. Factors associated with triptan use in episodic migraine: results from the American migraine prevalence and prevention study. Headache. 2012;52(2):213–23.PubMedCrossRef

20.

Kαllen B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011;34(8):691–703. doi:10.2165/11590370-000000000-00000.CrossRef

21.

Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache. 2001;41(4):351–6.PubMedCrossRef

22.

Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache. 2000;40(1):20–4.PubMedCrossRef

23.

GlaxoSmithKline. The Sumatriptan/Naratriptan/Treximet Pregnancy. 2012.

24.

Norwegian Institute of Public Health. The Medical Birth Registry of Norway. Oslo, Norway. http://www.fhi.no/helseregistre/medisinsk-fodselsregister (2013).

25.

Norwegian Institute of Public Health. The Norwegian Prescription Database. Oslo, Norway. http://www.fhi.no/helseregistre/reseptregisteret (2013).

26.

Al-Zirqi I, Stray-Pedersen B, Forsen L, Daltveit AK, Vangen S. Validation study of uterine rupture registration in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2013;. doi:10.1111/aogs.12148.PubMed

27.

Vikanes A, Magnus P, Vangen S, Lomsdal S, Grjibovski AM. Hyperemesis gravidarum in the Medical Birth Registry of Norway—a validity study. BMC Pregnancy Childbirth. 2012;12:115. doi:10.1186/1471-2393-12-115.PubMedCrossRef

28.

Engeland A, Bjorge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2009;88(10):1083–9. doi:10.1080/00016340903128454.PubMedCrossRef

29.

Melve KK, Lie RT, Skjaerven R, Van Der Hagen CB, Gradek GA, Jonsrud C, et al. Registration of down syndrome in the Medical Birth Registry of Norway: validity and time trends. Acta Obstet Gynecol Scand. 2008;87(8):824–30. doi:10.1080/00016340802217184.PubMedCrossRef

30.

Baghestan E, Bordahl PE, Rasmussen SA, Sande AK, Lyslo I, Solvang I. A validation of the diagnosis of obstetric sphincter tears in two Norwegian databases, the Medical Birth Registry and the Patient Administration System. Acta Obstet Gynecol Scand. 2007;86(2):205–9. doi:10.1080/00016340601111364.PubMedCrossRef

31.

Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435–9.PubMedCrossRef

32.

ATC/DDD Index 2008 [database on the Internet]. Available from: < http://www.whocc.no/atcddd/> (2009). Accessed 3 June 2009.

33.

World Health Organization. International Classification of Diseases. 2013. http://www.who.int/classifications/icd/en/.

34.

Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia. 2005;25(9):685–8. doi:10.1111/j.1468-2982.2004.00929.x.PubMedCrossRef

35.

Banhidy F, Acs N, Horvath-Puho E, Czeizel AE. Maternal severe migraine and risk of congenital limb deficiencies. Birth Defects Res A. 2006;76(8):592–601. doi:10.1002/bdra.20288.CrossRef

36.

Williams MA, Peterlin BL, Gelaye B, Enquobahrie DA, Miller RS, Aurora SK. Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs. Headache. 2011;51(10):1468–82. doi:10.1111/j.1526-4610.2011.01961.x.PubMedCrossRef

37.

Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf. 2003;26(2):93–107.PubMedCrossRef

38.

Gupta S, Hanff LM, Visser W, Steegers EA, Saxena PR, Vulto AG, et al. Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy. J Hypertens. 2006;24(7):1345–53. doi:10.1097/01.hjh.0000234115.40648.88.PubMedCrossRef

39.

Blair EM, Nelson KB. Migraine and preterm birth. J perinatol. 2011;31(6):434–9. doi:10.1038/jp.2010.148.PubMedCrossRef

40.

Marozio L, Facchinetti F, Allais G, Nappi RE, Enrietti M, Neri I, et al. Headache and adverse pregnancy outcomes: a prospective study. Eur J Obstet Gynecol Reprod Biol. 2012;161(2):140–3. doi:10.1016/j.ejogrb.2011.12.030.PubMedCrossRef

41.

Cripe SM, Sanchez S, Lam N, Sanchez E, Ojeda N, Tacuri S, et al. Depressive symptoms and migraine comorbidity among pregnant Peruvian women. J Affect Disord. 2010;122(1–2):149–53. doi:10.1016/j.jad.2009.07.014.PubMedCrossRef

42.

Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol. 2008;64(1):1–8. doi:10.1007/s00228-007-0391-4.PubMedCrossRef

43.

Melve K, Lie R, Skjærven R, Van Der Hagen C, Gradek G, Jonsrud C, et al. Registration of down syndrome in the Medical Birth Registry of Norway: validity and time trends. Acta Obstet Gynecol Scand. 2008;87:824–30.PubMedCrossRef

44.

Kubon C, Sivertsen A, Vindenes HA, Abyholm F, Wilcox A, Lie RT. Completeness of registration of oral clefts in a medical birth registry: a population-based study. Acta Obstet Gynecol Scand. 2007;86(12):1453–7. doi:10.1080/08037050701645090.PubMedCrossRef

Title: Triptan safety during pregnancy: a Norwegian population registry study
Authors: Kateřina Nezvalová-Henriksen
Olav Spigset
Hedvig Nordeng
Publication date: 01-09-2013
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 9/2013
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-013-9831-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Triptan safety during pregnancy: a Norwegian population registry study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2013

High cystatin C levels predict severe retinopathy in type 2 diabetes patients

The impact of including different study designs in meta-analyses of diagnostic accuracy studies

Serum C-peptide levels as an independent predictor of diabetes mellitus mortality in non-diabetic individuals

Early life exposures and the risk of adult glioma

Meta-analysis of diagnostic performance studies

Adverse childhood experiences and premature all-cause mortality